More about High-Yield Cash Accounts with M1
Brokerage Accounts
Retirement Accounts
Other Accounts
Quotes are delayed by 15 minutes.
1D
1W
1M
3M
6M
YTD
1Y
2Y
5Y
ALL
Market cap
$3.31B
EPS
-0.65
P/E ratio
--
Price to sales
8.44
Dividend yield
--
Beta
1.212063
Previous close
$55.38
Today's open
$55.15
Day's range
$54.50 - $56.87
52 week range
$23 - $59.72
show more
CEO
Michael Dale
Employees
622
Headquarters
Alachua, FL
Exchange
NASDAQ Capital Market
Shares outstanding
59730715
Issue type
Common Stock
Healthcare
Medical Equipment & Supplies
AxoGen: 3 Key Takeaways for Long-Term Investors
AxoGen raised full-year 2026 revenue guidance to at least $290 million. Commercial payer coverage for Avance reached 96% of covered U.S. lives.
The Motley Fool • Nov 16, 2026

AxoGen (AXGN) is a Great Momentum Stock: Should You Buy?
Does AxoGen (AXGN) have what it takes to be a top stock pick for momentum investors? Let's find out.
Zacks Investment Research • Nov 12, 2026

Axogen, Inc. (AXGN) Discusses Prostate Nerve Reconstruction Market Development Transcript
Axogen, Inc. (AXGN) Discusses Prostate Nerve Reconstruction Market Development Transcript
Seeking Alpha • Nov 9, 2026

Axogen, Inc. to Participate in Multiple Upcoming Investor Conferences
ALACHUA, Fla. and TAMPA, Fla., Nov. 03, 2026 (GLOBE NEWSWIRE) -- Axogen, Inc. (Nasdaq: AXGN), a global leader in developing and marketing innovative surgical solutions for the restoration of peripheral nerve function, today announced that management is scheduled to participate in three upcoming investor conferences:
GlobeNewsWire • Nov 3, 2026

GMED vs. AXGN: Which Stock Should Value Investors Buy Now?
Investors interested in stocks from the Medical - Instruments sector have probably already heard of Globus Medical (GMED) and AxoGen (AXGN). But which of these two companies is the best option for those looking for undervalued stocks?
Zacks Investment Research • Nov 2, 2026

Axogen: Taking The Friction Out Of Nerve Repair
Axogen (AXGN) is evolving from a growth story to the default procedural platform in peripheral nerve repair, protected by a regulatory moat for the next decade. Q3 2026 saw 26% revenue growth, 45% adjusted EBITDA growth, and operating leverage outpacing dilution, with guidance for at least $290M in 2026 sales and 73%+ gross margin. The $200M BioCircuit (NerveTape) acquisition eliminates technical barriers for surgeons, expands the addressable market, and is accretive at 5.9x expected 2027 sales.
Seeking Alpha • Oct 30, 2026

Is AxoGen (AXGN) Outperforming Other Medical Stocks This Year?
Here is how AxoGen (AXGN) and BioCryst Pharmaceuticals (BCRX) have performed compared to their sector so far this year.
Zacks Investment Research • Oct 29, 2026

AxoGen Q3 Earnings Call Highlights
AxoGen NASDAQ: AXGN reported third-quarter revenue growth of 26.2% as demand for its nerve-repair products increased across its breast, extremities, oral and maxillofacial, and head-and-neck markets. The company also raised its full-year revenue outlook following the October acquisition of BioCircuit and said it plans to begin prostate nerve reconstruction market-development activities in 2027.
MarketBeat • Oct 28, 2026

Axogen, Inc. (AXGN) Q3 2026 Earnings Call Transcript
Axogen, Inc. (AXGN) Q3 2026 Earnings Call Transcript
Seeking Alpha • Oct 28, 2026

Axogen, Inc. Reports Third Quarter 2026 Financial Results
Raises Full Year Revenue Guidance to at Least 29% Growth or $290 million Raises Full Year Revenue Guidance to at Least 29% Growth or $290 million
GlobeNewsWire • Oct 28, 2026

¹ Disclosures

Open an M1 investment account to buy and sell Axogen Inc. commission-free¹. Build wealth for the long term using automated trading and transfers.